Clinical Trial Update: A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib Therapy [Phase 3]

View source ↗

Summary

A Phase 3 randomized trial evaluating IDRX-42 (GSK6042981) versus sunitinib in patients with gastrointestinal stromal tumors after imatinib therapy, currently r…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastrointestinal Stromal Tumor

Drugs mentioned

• IDRX-42 (GSK6042981)
• Sutent (sunitinib)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Gastrointestinal Neoplasms | Phase 3 | Status: RECRUITING